We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
MacroGenics
MGNX
$243M
| $228K | ﹤0.01% |
188,711
| – | – |
|
902
Braze
BRZE
$2.89B
| $213K | ﹤0.01% |
+7,580
| New | +$240K |
|
903
Sprout Social
SPT
$514M
| $205K | ﹤0.01% |
+9,782
| New | +$207K |
|
|
CASI
904
DELISTED
CASI Pharmaceuticals
CASI
| $195K | ﹤0.01% |
165,640
+1,275
| +0.8% | +$2.34K |
|
905
Xponential Fitness
XPOF
$278M
| $174K | ﹤0.01% |
23,274
| – | – |
|
906
Caribou Biosciences
CRBU
$149M
| $155K | ﹤0.01% |
122,833
+698
| +0.6% | +$686 |
|
|
BIOA
907
BioAge Labs
BIOA
$479M
| $130K | ﹤0.01% |
31,565
| – | – |
|
|
JAMF
908
DELISTED
Jamf
JAMF
| $126K | ﹤0.01% |
+13,208
| New | +$142K |
|
|
IGMS
909
DELISTED
IGM Biosciences
IGMS
| $77.9K | ﹤0.01% |
69,576
| – | – |
|
|
SGMO
910
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $15.6K | ﹤0.01% |
28,859
+9,619
| +50% | +$5.71K |
|
911
Neumora Therapeutics
NMRA
$304M
| $11K | ﹤0.01% |
14,957
| – | – |
|
912
American Airlines Group
AAL
$10.6B
| – | – |
-779,772
| Closed | -$8.23M |
|
913
AdaptHealth
AHCO
$1.47B
| – | – |
-262,989
| Closed | -$2.85M |
|
914
C3.ai
AI
$1.51B
| – | – |
-16,426
| Closed | -$346K |
|
915
Allegro MicroSystems
ALGM
$7.74B
| – | – |
-19,222
| Closed | -$483K |
|
916
Alignment Healthcare
ALHC
$3.02B
| – | – |
-115,021
| Closed | -$2.14M |
|
917
Alarm.com
ALRM
$2.75B
| – | – |
-9,233
| Closed | -$514K |
|
918
Ambarella
AMBA
$3.63B
| – | – |
-441,385
| Closed | -$22.2M |
|
919
Amneal Pharmaceuticals
AMRX
$6.02B
| – | – |
-1,504,095
| Closed | -$12.6M |
|
920
ANI Pharmaceuticals
ANIP
$1.82B
| – | – |
-166,448
| Closed | -$11.1M |
|
921
APA Corp
APA
$13B
| – | – |
-14,659
| Closed | -$308K |
|
922
Amphenol
APH
$201B
| – | – |
-457,723
| Closed | -$30M |
|
923
ARK Genomic Revolution ETF
ARKG
$1.6B
| – | – |
-62,368
| Closed | -$1.29M |
|
924
Arm
ARM
$255B
| – | – |
-45,802
| Closed | -$4.89M |
|
925
Arvinas
ARVN
$520M
| – | – |
-695,945
| Closed | -$4.89M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.